健世科技-B(09877.HK)公佈年度業績 虧損大幅收窄至1.86億元 加快核心產品於全球範圍應用的進程
格隆匯3月21日丨健世科技-B(09877.HK)公吿,截至2024年12月31日止年度,公司其他收入及收益達4156萬元人民幣,年內虧損大幅收窄至1.86億元,上年同期虧損3.79億元。
截至本公吿日期,公司有多款處於不同商業化、研發階段的產品,覆蓋包含經導管三尖瓣介入治療、經導管主動脈瓣介入治療、經導管二尖瓣介入治療在內的多種常見結構性心臟病治療領域。公司近期的經營重點將集中於經導管三尖瓣介入置換產品LuX-Valve系列的全球推廣,以及經導管主動脈瓣介入置換產品Ken-Valve的商業化。
就LuX-Valve系列產品,公司將通過在全球多個國家及地區開展註冊臨牀試驗及獲取批准、持續擴大業務發展區域、建立國際戰略合作等多元化方式,奠定此係列產品的全球技術優勢,併為後續其他重點產品提供幫助。就已獲得國家藥監局批准註冊的Ken-Valve產品,公司已就該產品生產和銷售獲得相關許可,啟動了多個省、直轄市、自治區的掛網申報工作,並且已於多家醫院向其術者及團隊進行了術式教育和產品推廣。公司正在積極推動其商業化相關工作,預計於2025年上半年實現商業化植入。
截至本公吿日期,公司擁有:三款核心產品,以及多款處於不同開發階段的其他在研產品;及於超過19個國家或地區擁有197項已授權專利及214項專利申請。
公司的願景是成為一個全球領先的醫療器械企業,提供治療結構性心臟病的全面創新產品。公司計劃實施以下戰略以實現公司的目標:加快核心產品於全球範圍應用的進程,以滿足全球患者龐大而急迫的結構性心臟病治療需求;專注於結構性心臟病及以公司的產品研發能力為基礎並尋求戰略合作以優化產品組合;及擴大公司的產品覆蓋,以成為行業領導者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.